Asset sale Announced

AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031

US$630m consideration

Announced 20 Jan 2026

Advisers

AbelZeta's 50% share of China development and commercialisation rights to C-CAR031

Target

AstraZeneca

Acquirer

Not disclosed

Target
AbelZeta's 50% share of China development and commercialisation rights to C-CAR031
Acquirer
AstraZeneca
Seller
AbelZeta
Target based in
China
Buyer based in
United Kingdom
Seller based in
China (unverified)
Sector
Biotech
Tags
Biotech, Cell Therapy, Oncology

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.